Skip to content

The Relationship Between Neuropsychological Testing and MRI, PET and COBRE - Project 1: AIM 2 (GE-180)

The Relationship Between Neuropsychological Testing and MRI, PET and Blood Biomarkers in Neurodegenerative Disease (COBRE - Project 1): AIM 2

Status
Terminated
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03702816
Enrollment
24
Registered
2018-10-11
Start date
2018-12-13
Completion date
2019-09-29
Last updated
2023-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer Disease, Inflammation, Parkinson Disease

Keywords

neuroinflammation

Brief summary

The complex pathological cascades leading to both Alzheimer's disease (AD) and Parkinson's disease (PD) involve, at various points, inflammation. Since inflammation is a treatable symptom, understanding how and when it impacts the brain, and where specifically in the brain, would offer important guidance in the development of new treatments, sorely needed in both diseases. Microglia play an important anti-inflammatory role, and produce a substance, mitochondrial translocator protein (TSPO), whose presence can be used as a marker of regional inflammation. GE180 is a newly developed PET ligand which binds to TSPO and hence can be used in imaging studies to analyze regional inflammation in living patients. In prior studies it has shown regional specificity in multiple sclerosis and brain injury. In the current study, the investigators will be using GE180 to analyze regional and global inflammation in the brains of patients with AD and PD at a single time point. The results of the current study will provide enriched understanding of inflammation in these conditions, and potentially provide preliminary data to inform design of future interventional trials.

Detailed description

This study will involve a cohort that is currently being established at the Cleveland Clinic Lou Ruvo Center for Brain Health. The cohort has been established under the NIH Center of Biomedical Research Excellence (COBRE) grant and involves annual collection of detailed neuropsychological testing and biomarkers (blood and neuroimaging) from all participants annually. Data are filed in a registry (CNTN). Participants include healthy controls, participants with PD (with and without mild cognitive impairment (MCI)) and patients with MCI (with or without positive florbetapir scan, which demonstrates underlying AD changes likely causing the cognitive impairment) and patients with AD. For the current study, we will focus on patients with MCI with associated underlying AD or PD. Participants will undergo GE180 PET one time during the study. The approach to PET data collection and analysis will be similar to work done previously with an earlier generation ligand (Edison et al., 2008) and to other work with this tracer (Fan et al., 2016). Participants will complete ECGs and have their vitals taken prior to and immediately following injections. Briefly, the ligand will be injected, there will be a 90 minute uptake period, and scan acquisition will commence for 30 minutes, and will be collected in list mode and rebinned into 18 time frames post acquisition. The total duration of the study visit will be around 4 hours, and the participants will receive $50 compensation for the visit.

Interventions

DRUGGE180 PET Scan

GE180 PET Scan

Sponsors

Aaron Ritter, MD
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Masking description

No masking

Intervention model description

All participants will receive one Flutriciclamide (18F-GE180) PET scan.

Eligibility

Sex/Gender
ALL
Age
55 Years to 90 Years
Healthy volunteers
Yes

Inclusion criteria

1. Be enrolled in CNTN 2. Aged 55 to 90 3. Available study partners 4. Willing and able to participate in longitudinal follow-up study 5. For MCI patients, fit criteria based in Movement Disorders Task Force or NIA

Exclusion criteria

1. Significant neurological disorders other than AD or PD; 2. Unstable medical conditions 3. History of major psychiatric diseases 4. MRI evidence of infarction or other focal lesion or multiple lacunes 5. Clinically significant abnormalities in B12 or TSH 6. Identified as having a common polymorphism (rs6971) in the TSPO gene which has been shown to reduce binding affinity of tracers similar to GE180. This testing will be done as part of their CNTN participation.

Design outcomes

Primary

MeasureTime frameDescription
Frontal GE180 Standardized Uptake Value Ratio (SUVR)Baseline (Single scan)Frontal SUVR- GE180 binding potential in the frontal cortical ROI, as a marker of frontal neuroinflammation. Frontal neuroinflammation would be expected to relate to frontal lobe AD pathology, and given known frontal lobe role in executive system function, is hypothesized to relate to measures of executive function in particular, and also to memory and language dysfunction, as these have executive components. Greater frontal lobe GE180 is expected to relate to poorer cognitive function.
Cingulate GE180 Standardized Uptake Value Ratio (SUVR)Baseline (Single scan)Cingulate SUVR- GE180 binding potential in the cingulate ROI, as a marker of cingulate neuroinflammation. Cingulate neuroinflammation would be expected to relate to cingulate AD pathology, and given known cingulate lobe role in executive system function, is hypothesized to relate to measures of executive function in particular, with greater cingulate GE180 relating to poorer cognitive function.
Parietal GE180 Standardized Uptake Value Ratio (SUVR)Baseline (Single scan)Parietal SUVR - GE180 binding potential in the parietal cortical ROI, as a marker of parietal neuroinflammation. Parietal neuroinflammation would be expected to relate to parietal lobe AD pathology, and given known parietal lobe role in visual and executive system function, is hypothesized to relate to measures of visuospatial and executive skills in particular, with greater parietal lobe GE180 relating to poorer cognitive function.
Temporal GE180 Standardized Uptake Value Ratio (SUVR)Baseline (Single scan)Temporal SUVR-- GE180 binding potential in the temporal cortical ROI, as a marker of temporal neuroinflammation. Temporal neuroinflammation would be expected to relate to temporal lobe AD pathology, and given known temporal lobe role in memory and language system function, is hypothesized to relate to measures of memory in particular, with greater temporal lobe GE180 relating to poorer memory and language function.
Whole Brain GE180 Standardized Uptake Value Ratio (SUVR)Baseline (Single scan)Whole Brain GE180- GE180 binding potential in the whole brain, as a marker of global neuroinflammation. Global neuroinflammation would be expected to relate to more widespread pathology on average, and is hypothesized to relate to global measures of cognition, including the MoCA and DRS, with greater whole brain GE180 relating to poorer cognitive function overall.
Memory Composite Score (Z-score)Baseline (Pre-scan)The memory composite score is comprised from data from two gold-standard clinical measures of verbal and nonverbal memory (Rey Auditory Verbal Learning Test, delayed recall score; Brief Visuospatial Memory Test, Revised, delayed recall score). The raw score for each individual assessment is corrected for age based on published normative data for each test. These adjusted scores (T scores and/or scaled scores) are converted to z-scores, then the two z-scores are averaged together to create the composite score. A higher value is indicative of better memory function, a lower value is indicative of worse memory function. A z-score of 0 represents the sample mean. Composite Z-scores do not have direct clinical relevance.
Executive Function Composite Score (Z-score)Baseline (Pre-scan)The executive function composite score is comprised from data from two gold-standard clinical measures of set-shifting and inhibition (Trail Making Test, part B; Delis Kaplan Executive Functioning Scale Color Word Inhibition, inhibition score). The raw score for each individual assessment is corrected for age based on published normative data for each test. These adjusted scores (T scores and/or scaled scores) are converted to z-scores, then the two z-scores are averaged together to create the composite score. A higher value is indicative of better executive function, a lower value is indicative of worse executive function. A z-score of 0 represents the sample mean. Composite Z-scores do not have direct clinical relevance.
Speed Composite Score (Z-score)Baseline (Pre-scan)The speed composite score is comprised from data from two gold-standard clinical measures of speeded attention and psychomotor speed (Trail Making Test, part A; Symbol Digit Modalities Test, oral version). The raw score for the Symbol Digit Modalities Test, oral version is converted directly to a z-score based on published normative data. The Trail making Test, part A is corrected for age based on published normative data, resulting in a T-score, which is then converted to a z-score. Then the two z-scores are averaged together to create the composite score. A higher value is indicative of better speed function, a lower value is indicative of worse speed function. A z-score of 0 represents the sample mean. Composite Z-scores do not have direct clinical relevance.
Language Composite Score (Z-score)Baseline (Pre-scan)The language composite score is comprised from data from two gold-standard clinical measures of confrontation naming and semantic fluency (Boston Naming Test; Animal Naming Test). The raw score for the Animal Naming Test is converted directly to a z-score based on published normative data. The Boston Naming Test is corrected for age based on published normative data, resulting in a scaled score, which is then converted to a z-score. Then the two z-scores are averaged together to create the composite score. A higher value is indicative of better language function, a lower value is indicative of worse language function. A z-score of 0 represents the sample mean. Composite Z-scores do not have direct clinical relevance.
Dementia Rating ScoreBaseline (Pre-scan)DRS- The Dementia Rating Scale is a comprehensive, but relatively brief assessment of overall cognitive functioning. The measure consists of items testing memory, attention, executive skills, and visuospatial skill, for a total of 144 points. A score of less than 124 is indicative of dementia level cognitive functioning. A higher score indicates a better outcome.
Montreal Cognitive Assessment Score (MoCA)Baseline (Pre-scan)MoCA -The Montreal Cognitive Assessment is a brief screening tool, originally designed to detect patients with MCI in a memory disorders clinic \[10\]. Standard administration consists of 12 individual tasks grouped into seven cognitive domains (visuospatial/executive, naming; attention, language, abstraction, memory, and orientation). Task performance is summed generating both domain and a total score. An education correction of one point is added to the total score for individuals with 12 years of education or less. Scores range from 0-30, with a score of 26 or less indicating cognitive impairment.

Countries

United States

Participant flow

Participants by arm

ArmCount
Control
Control Group GE180 PET Scan, 2 μg/mL IV, 185MBq
10
Mild Cognitive Impairment
Mild Cognitive Impairment GE180 PET Scan, 2 μg/mL IV, 185MBq
7
Alzheimer's Disease
Alzheimer's Disease GE180 PET Scan, 2 μg/mL IV, 185MBq
3
Parkinson's Disease
Parkinson's Disease GE180 PET Scan, 2 μg/mL IV, 185MBq
4
Total24

Baseline characteristics

CharacteristicControlMild Cognitive ImpairmentAlzheimer's DiseaseParkinson's DiseaseTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
7 Participants6 Participants2 Participants4 Participants19 Participants
Age, Categorical
Between 18 and 65 years
3 Participants1 Participants1 Participants0 Participants5 Participants
Age, Continuous71.6 years
STANDARD_DEVIATION 7.96
75.7 years
STANDARD_DEVIATION 11.22
74 years
STANDARD_DEVIATION 10.23
74.7 years
STANDARD_DEVIATION 3.49
72.2 years
STANDARD_DEVIATION 8.96
Ethnicity (NIH/OMB)
Hispanic or Latino
1 Participants0 Participants0 Participants0 Participants1 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
9 Participants7 Participants3 Participants4 Participants23 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
1 Participants0 Participants0 Participants0 Participants1 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
2 Participants1 Participants0 Participants0 Participants3 Participants
Race (NIH/OMB)
White
7 Participants6 Participants3 Participants4 Participants20 Participants
Region of Enrollment
United States
10 participants7 participants3 participants4 participants24 participants
Sex: Female, Male
Female
5 Participants3 Participants2 Participants0 Participants10 Participants
Sex: Female, Male
Male
5 Participants4 Participants1 Participants4 Participants14 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
deaths
Total, all-cause mortality
0 / 100 / 70 / 30 / 4
other
Total, other adverse events
1 / 102 / 71 / 30 / 4
serious
Total, serious adverse events
0 / 100 / 70 / 30 / 4

Outcome results

Primary

Cingulate GE180 Standardized Uptake Value Ratio (SUVR)

Cingulate SUVR- GE180 binding potential in the cingulate ROI, as a marker of cingulate neuroinflammation. Cingulate neuroinflammation would be expected to relate to cingulate AD pathology, and given known cingulate lobe role in executive system function, is hypothesized to relate to measures of executive function in particular, with greater cingulate GE180 relating to poorer cognitive function.

Time frame: Baseline (Single scan)

ArmMeasureValue (MEAN)Dispersion
ControlCingulate GE180 Standardized Uptake Value Ratio (SUVR)0.9994 SUVRStandard Deviation 0.057
Mild Cognitive ImpairmentCingulate GE180 Standardized Uptake Value Ratio (SUVR)1.0387 SUVRStandard Deviation 0.036
Alzheimer's DiseaseCingulate GE180 Standardized Uptake Value Ratio (SUVR)1.0554 SUVRStandard Deviation 0.063
Parkinson's DiseaseCingulate GE180 Standardized Uptake Value Ratio (SUVR)0.9893 SUVRStandard Deviation 0.092
Comparison: Linear Regression of Memory Composite Scores and Cingulate GE180 SUVR in Control Subjectsp-value: 0.54Regression, Linear
Comparison: Linear Regression of Executive Function Composite Scores and Cingulate GE180 SUVR in Control Subjectsp-value: 0.53Regression, Linear
Comparison: Linear Regression of Speed Composite Scores and Cingulate GE180 SUVR in Control Subjectsp-value: 0.23Regression, Linear
Comparison: Linear Regression of Language Composite Scores and Cingulate GE180 SUVR in Control Subjectsp-value: 0.01Regression, Linear
Comparison: Linear Regression of Memory Composite Scores and Cingulate GE180 SUVR in MCI Subjectsp-value: 0.039Regression, Linear
Comparison: Linear Regression of Executive Function Composite Scores and Cingulate GE180 SUVR in MCI Subjectsp-value: 0.33Regression, Linear
Comparison: Linear Regression of Speed Composite Scores and Cingulate GE180 SUVR in MCI Subjectsp-value: 0.07Regression, Linear
Comparison: Linear Regression of Language Composite Scores and Cingulate GE180 SUVR in MCI Subjectsp-value: 0.03Regression, Linear
Comparison: Linear Regression of Memory Composite Scores and Cingulate GE180 SUVR in AD Subjectsp-value: 0.27Regression, Linear
Comparison: Linear Regression of Executive Function Composite Scores and Cingulate GE180 SUVR in AD Subjectsp-value: 0.16Regression, Linear
Comparison: Linear Regression of Speed Composite Scores and Cingulate GE180 SUVR in AD Subjectsp-value: 0.262Regression, Linear
Comparison: Linear Regression of Language Composite Scores and Cingulate GE180 SUVR in AD Subjectsp-value: 0.043Regression, Linear
Comparison: Linear Regression of Memory Composite Scores and Cingulate GE180 SUVR in PD Subjectsp-value: 0.26Regression, Linear
Comparison: Linear Regression of Executive Function Composite Scores and Cingulate GE180 SUVR in PD Subjectsp-value: 0.38Regression, Linear
Comparison: Linear Regression of Speed Composite Scores and Cingulate GE180 SUVR in PD Subjectsp-value: 0.07Regression, Linear
Comparison: Linear Regression of Language Composite Scores and Cingulate GE180 SUVR in PD Subjectsp-value: 0.37Regression, Linear
Primary

Dementia Rating Score

DRS- The Dementia Rating Scale is a comprehensive, but relatively brief assessment of overall cognitive functioning. The measure consists of items testing memory, attention, executive skills, and visuospatial skill, for a total of 144 points. A score of less than 124 is indicative of dementia level cognitive functioning. A higher score indicates a better outcome.

Time frame: Baseline (Pre-scan)

ArmMeasureValue (MEAN)Dispersion
ControlDementia Rating Score139.2 score on a scaleStandard Deviation 2.97
Mild Cognitive ImpairmentDementia Rating Score130.4 score on a scaleStandard Deviation 3.87
Alzheimer's DiseaseDementia Rating Score120.3 score on a scaleStandard Deviation 12.42
Parkinson's DiseaseDementia Rating Score139.3 score on a scaleStandard Deviation 5.25
Primary

Executive Function Composite Score (Z-score)

The executive function composite score is comprised from data from two gold-standard clinical measures of set-shifting and inhibition (Trail Making Test, part B; Delis Kaplan Executive Functioning Scale Color Word Inhibition, inhibition score). The raw score for each individual assessment is corrected for age based on published normative data for each test. These adjusted scores (T scores and/or scaled scores) are converted to z-scores, then the two z-scores are averaged together to create the composite score. A higher value is indicative of better executive function, a lower value is indicative of worse executive function. A z-score of 0 represents the sample mean. Composite Z-scores do not have direct clinical relevance.

Time frame: Baseline (Pre-scan)

ArmMeasureValue (MEAN)Dispersion
ControlExecutive Function Composite Score (Z-score)0.572 z scoreStandard Deviation 0.9
Mild Cognitive ImpairmentExecutive Function Composite Score (Z-score)-0.011 z scoreStandard Deviation 0.42
Alzheimer's DiseaseExecutive Function Composite Score (Z-score)-1.361 z scoreStandard Deviation 1.99
Parkinson's DiseaseExecutive Function Composite Score (Z-score)0.029 z scoreStandard Deviation 0.9
Primary

Frontal GE180 Standardized Uptake Value Ratio (SUVR)

Frontal SUVR- GE180 binding potential in the frontal cortical ROI, as a marker of frontal neuroinflammation. Frontal neuroinflammation would be expected to relate to frontal lobe AD pathology, and given known frontal lobe role in executive system function, is hypothesized to relate to measures of executive function in particular, and also to memory and language dysfunction, as these have executive components. Greater frontal lobe GE180 is expected to relate to poorer cognitive function.

Time frame: Baseline (Single scan)

ArmMeasureValue (MEAN)Dispersion
ControlFrontal GE180 Standardized Uptake Value Ratio (SUVR)0.8893 SUVRStandard Deviation 0.058
Mild Cognitive ImpairmentFrontal GE180 Standardized Uptake Value Ratio (SUVR)0.9436 SUVRStandard Deviation 0.055
Alzheimer's DiseaseFrontal GE180 Standardized Uptake Value Ratio (SUVR)0.8855 SUVRStandard Deviation 0.036
Parkinson's DiseaseFrontal GE180 Standardized Uptake Value Ratio (SUVR)0.8850 SUVRStandard Deviation 0.049
Comparison: Linear Regression of Memory Composite Scores and Frontal GE180 SUVR in Control Subjectsp-value: 0.6Regression, Linear
Comparison: Linear Regression of Executive Function Composite Scores and Frontal GE180 SUVR in Control Subjectsp-value: 0.56Regression, Linear
Comparison: Linear Regression of Speed Composite Scores and Frontal GE180 SUVR in Control Subjectsp-value: 0.44Regression, Linear
Comparison: Linear Regression of Language Composite Scores and Frontal GE180 SUVR in Control Subjectsp-value: 0.15Regression, Linear
Comparison: Linear Regression of Memory Composite Scores and Frontal GE180 SUVR in MCI Subjectsp-value: 0.39Regression, Linear
Comparison: Linear Regression of Executive Function Composite Scores and Frontal GE180 SUVR in MCI Subjectsp-value: 0.95Regression, Linear
Comparison: Linear Regression of Speed Composite Scores and Frontal GE180 SUVR in MCI Subjectsp-value: 0.53Regression, Linear
Comparison: Linear Regression of Language Composite Scores and Frontal GE180 SUVR in MCI Subjectsp-value: 0.19Regression, Linear
Comparison: Linear Regression of Memory Composite Scores and Frontal GE180 SUVR in AD Subjectsp-value: 0.32Regression, Linear
Comparison: Linear Regression of Executive Function Composite Scores and Frontal GE180 SUVR in AD Subjectsp-value: 0.11Regression, Linear
Comparison: Linear Regression of Speed Composite Scores and Frontal GE180 SUVR in AD Subjectsp-value: 0.31Regression, Linear
Comparison: Linear Regression of Language Composite Scores and Frontal GE180 SUVR in AD Subjectsp-value: 0.005Regression, Linear
Comparison: Linear Regression of Memory Composite Scores and Frontal GE180 SUVR in PD Subjectsp-value: 0.84Regression, Linear
Comparison: Linear Regression of Executive Function Composite Scores and Frontal GE180 SUVR in PD Subjectsp-value: 0.94Regression, Linear
Comparison: Linear Regression of Speed Composite Scores and Frontal GE180 SUVR in PD Subjectsp-value: 0.29Regression, Linear
Comparison: Linear Regression of Language Composite Scores and Frontal GE180 SUVR in PD Subjectsp-value: 0.72Regression, Linear
Primary

Language Composite Score (Z-score)

The language composite score is comprised from data from two gold-standard clinical measures of confrontation naming and semantic fluency (Boston Naming Test; Animal Naming Test). The raw score for the Animal Naming Test is converted directly to a z-score based on published normative data. The Boston Naming Test is corrected for age based on published normative data, resulting in a scaled score, which is then converted to a z-score. Then the two z-scores are averaged together to create the composite score. A higher value is indicative of better language function, a lower value is indicative of worse language function. A z-score of 0 represents the sample mean. Composite Z-scores do not have direct clinical relevance.

Time frame: Baseline (Pre-scan)

ArmMeasureValue (MEAN)Dispersion
ControlLanguage Composite Score (Z-score)0.584 z scoreStandard Deviation 0.857
Mild Cognitive ImpairmentLanguage Composite Score (Z-score)-0.234 z scoreStandard Deviation 1.12
Alzheimer's DiseaseLanguage Composite Score (Z-score)-0.7272 z scoreStandard Deviation 0.92
Parkinson's DiseaseLanguage Composite Score (Z-score)0.541 z scoreStandard Deviation 1.18
Primary

Memory Composite Score (Z-score)

The memory composite score is comprised from data from two gold-standard clinical measures of verbal and nonverbal memory (Rey Auditory Verbal Learning Test, delayed recall score; Brief Visuospatial Memory Test, Revised, delayed recall score). The raw score for each individual assessment is corrected for age based on published normative data for each test. These adjusted scores (T scores and/or scaled scores) are converted to z-scores, then the two z-scores are averaged together to create the composite score. A higher value is indicative of better memory function, a lower value is indicative of worse memory function. A z-score of 0 represents the sample mean. Composite Z-scores do not have direct clinical relevance.

Time frame: Baseline (Pre-scan)

ArmMeasureValue (MEAN)Dispersion
ControlMemory Composite Score (Z-score)0.367 z scoreStandard Deviation 0.86
Mild Cognitive ImpairmentMemory Composite Score (Z-score)-0.675 z scoreStandard Deviation 1.42
Alzheimer's DiseaseMemory Composite Score (Z-score)-2.483 z scoreStandard Deviation 0.35
Parkinson's DiseaseMemory Composite Score (Z-score)-0.404 z scoreStandard Deviation 0.88
Primary

Montreal Cognitive Assessment Score (MoCA)

MoCA -The Montreal Cognitive Assessment is a brief screening tool, originally designed to detect patients with MCI in a memory disorders clinic \[10\]. Standard administration consists of 12 individual tasks grouped into seven cognitive domains (visuospatial/executive, naming; attention, language, abstraction, memory, and orientation). Task performance is summed generating both domain and a total score. An education correction of one point is added to the total score for individuals with 12 years of education or less. Scores range from 0-30, with a score of 26 or less indicating cognitive impairment.

Time frame: Baseline (Pre-scan)

ArmMeasureValue (MEAN)Dispersion
ControlMontreal Cognitive Assessment Score (MoCA)26.0 score on a scaleStandard Deviation 2.36
Mild Cognitive ImpairmentMontreal Cognitive Assessment Score (MoCA)23.4 score on a scaleStandard Deviation 2.44
Alzheimer's DiseaseMontreal Cognitive Assessment Score (MoCA)18.3 score on a scaleStandard Deviation 4.73
Parkinson's DiseaseMontreal Cognitive Assessment Score (MoCA)27.5 score on a scaleStandard Deviation 1
Primary

Parietal GE180 Standardized Uptake Value Ratio (SUVR)

Parietal SUVR - GE180 binding potential in the parietal cortical ROI, as a marker of parietal neuroinflammation. Parietal neuroinflammation would be expected to relate to parietal lobe AD pathology, and given known parietal lobe role in visual and executive system function, is hypothesized to relate to measures of visuospatial and executive skills in particular, with greater parietal lobe GE180 relating to poorer cognitive function.

Time frame: Baseline (Single scan)

ArmMeasureValue (MEAN)Dispersion
ControlParietal GE180 Standardized Uptake Value Ratio (SUVR)0.8701 SUVRStandard Deviation 0.0588
Mild Cognitive ImpairmentParietal GE180 Standardized Uptake Value Ratio (SUVR)0.9241 SUVRStandard Deviation 0.043
Alzheimer's DiseaseParietal GE180 Standardized Uptake Value Ratio (SUVR)0.8847 SUVRStandard Deviation 0.032
Parkinson's DiseaseParietal GE180 Standardized Uptake Value Ratio (SUVR)0.8562 SUVRStandard Deviation 0.032
Comparison: Linear Regression of Memory Composite Scores and Parietal GE180 SUVR in Control Subjectsp-value: 0.64Regression, Linear
Comparison: Linear Regression of Executive Function Composite Scores and Parietal GE180 SUVR in Control Subjectsp-value: 0.92Regression, Linear
Comparison: Linear Regression of Speed Composite Scores and Parietal GE180 SUVR in Control Subjectsp-value: 0.22Regression, Linear
Comparison: Linear Regression of Language Composite Scores and Parietal GE180 SUVR in Control Subjectsp-value: 0.42Regression, Linear
Comparison: Linear Regression of Memory Composite Scores and Parietal GE180 SUVR in MCI Subjectsp-value: 0.61Regression, Linear
Comparison: Linear Regression of Executive Function Composite Scores and Parietal GE180 SUVR in MCI Subjectsp-value: 0.95Regression, Linear
Comparison: Linear Regression of Speed Composite Scores and Parietal GE180 SUVR in MCI Subjectsp-value: 0.55Regression, Linear
Comparison: Linear Regression of Language Composite Scores and Parietal GE180 SUVR in MCI Subjectsp-value: 0.43Regression, Linear
Comparison: Linear Regression of Memory Composite Scores and Parietal GE180 SUVR in AD Subjectsp-value: 0.036Regression, Linear
Comparison: Linear Regression of Executive Function Composite Scores and Parietal GE180 SUVR in AD Subjectsp-value: 0.39Regression, Linear
Comparison: Linear Regression of Speed Composite Scores and Parietal GE180 SUVR in AD Subjectsp-value: 0.031Regression, Linear
Comparison: Linear Regression of Language Composite Scores and Parietal GE180 SUVR in AD Subjectsp-value: 0.274Regression, Linear
Comparison: Linear Regression of Memory Composite Scores and Parietal GE180 SUVR in PD Subjectsp-value: 0.66Regression, Linear
Comparison: Linear Regression of Executive Function Composite Scores and Parietal GE180 SUVR in PD Subjectsp-value: 0.07Regression, Linear
Comparison: Linear Regression of Speed Composite Scores and Parietal GE180 SUVR in PD Subjectsp-value: 0.48Regression, Linear
Comparison: Linear Regression of Language Composite Scores and Parietal GE180 SUVR in PD Subjectsp-value: 0.12Regression, Linear
Primary

Speed Composite Score (Z-score)

The speed composite score is comprised from data from two gold-standard clinical measures of speeded attention and psychomotor speed (Trail Making Test, part A; Symbol Digit Modalities Test, oral version). The raw score for the Symbol Digit Modalities Test, oral version is converted directly to a z-score based on published normative data. The Trail making Test, part A is corrected for age based on published normative data, resulting in a T-score, which is then converted to a z-score. Then the two z-scores are averaged together to create the composite score. A higher value is indicative of better speed function, a lower value is indicative of worse speed function. A z-score of 0 represents the sample mean. Composite Z-scores do not have direct clinical relevance.

Time frame: Baseline (Pre-scan)

ArmMeasureValue (MEAN)Dispersion
ControlSpeed Composite Score (Z-score)0.285 z scoreStandard Deviation 1.28
Mild Cognitive ImpairmentSpeed Composite Score (Z-score)-0.013 z scoreStandard Deviation 0.78
Alzheimer's DiseaseSpeed Composite Score (Z-score)-1.585 z scoreStandard Deviation 1.06
Parkinson's DiseaseSpeed Composite Score (Z-score)-0.731 z scoreStandard Deviation 0.6
Primary

Temporal GE180 Standardized Uptake Value Ratio (SUVR)

Temporal SUVR-- GE180 binding potential in the temporal cortical ROI, as a marker of temporal neuroinflammation. Temporal neuroinflammation would be expected to relate to temporal lobe AD pathology, and given known temporal lobe role in memory and language system function, is hypothesized to relate to measures of memory in particular, with greater temporal lobe GE180 relating to poorer memory and language function.

Time frame: Baseline (Single scan)

ArmMeasureValue (MEAN)Dispersion
ControlTemporal GE180 Standardized Uptake Value Ratio (SUVR)0.9127 SUVRStandard Deviation 0.0668
Mild Cognitive ImpairmentTemporal GE180 Standardized Uptake Value Ratio (SUVR)0.9779 SUVRStandard Deviation 0.046
Alzheimer's DiseaseTemporal GE180 Standardized Uptake Value Ratio (SUVR)0.9146 SUVRStandard Deviation 0.045
Parkinson's DiseaseTemporal GE180 Standardized Uptake Value Ratio (SUVR)0.8899 SUVRStandard Deviation 0.056
Comparison: Linear Regression of Memory Composite Scores and Temporal GE180 SUVR in Control Subjectsp-value: 0.85Regression, Linear
Comparison: Linear Regression of Executive Function Composite Scores and Temporal GE180 SUVR in Control Subjectsp-value: 0.84Regression, Linear
Comparison: Linear Regression of Speed Composite Scores and Temporal GE180 SUVR in Control Subjectsp-value: 0.35Regression, Linear
Comparison: Linear Regression of Language Composite Scores and Temporal GE180 SUVR in Control Subjectsp-value: 0.25Regression, Linear
Comparison: Linear Regression of Memory Composite Scores and Temporal GE180 SUVR in MCI Subjectsp-value: 0.25Regression, Linear
Comparison: Linear Regression of Executive Function Composite Scores and Temporal GE180 SUVR in MCI Subjectsp-value: 0.54Regression, Linear
Comparison: Linear Regression of Speed Composite Scores and Temporal GE180 SUVR in MCI Subjectsp-value: 0.47Regression, Linear
Comparison: Linear Regression of Language Composite Scores and Temporal GE180 SUVR in MCI Subjectsp-value: 0.74Regression, Linear
Comparison: Linear Regression of Memory Composite Scores and Temporal GE180 SUVR in AD Subjectsp-value: 0.83Regression, Linear
Comparison: Linear Regression of Executive Function Composite Scores and Temporal GE180 SUVR in AD Subjectsp-value: 0.41Regression, Linear
Comparison: Linear Regression of Speed Composite Scores and Temporal GE180 SUVR in AD Subjectsp-value: 0.83Regression, Linear
Comparison: Linear Regression of Language Composite Scores and Temporal GE180 SUVR in AD Subjectsp-value: 0.52Regression, Linear
Comparison: Linear Regression of Memory Composite Scores and Temporal GE180 SUVR in PD Subjectsp-value: 0.98Regression, Linear
Comparison: Linear Regression of Executive Function Composite Scores and Temporal GE180 SUVR in PD Subjectsp-value: 0.95Regression, Linear
Comparison: Linear Regression of Speed Composite Scores and Temporal GE180 SUVR in PD Subjectsp-value: 0.32Regression, Linear
Comparison: Linear Regression of Language Composite Scores and Temporal GE180 SUVR in PD Subjectsp-value: 0.67Regression, Linear
Primary

Whole Brain GE180 Standardized Uptake Value Ratio (SUVR)

Whole Brain GE180- GE180 binding potential in the whole brain, as a marker of global neuroinflammation. Global neuroinflammation would be expected to relate to more widespread pathology on average, and is hypothesized to relate to global measures of cognition, including the MoCA and DRS, with greater whole brain GE180 relating to poorer cognitive function overall.

Time frame: Baseline (Single scan)

ArmMeasureValue (MEAN)Dispersion
ControlWhole Brain GE180 Standardized Uptake Value Ratio (SUVR)0.9179 SUVRStandard Deviation 0.0545
Mild Cognitive ImpairmentWhole Brain GE180 Standardized Uptake Value Ratio (SUVR)0.9711 SUVRStandard Deviation 0.034
Alzheimer's DiseaseWhole Brain GE180 Standardized Uptake Value Ratio (SUVR)0.9351 SUVRStandard Deviation 0.01
Parkinson's DiseaseWhole Brain GE180 Standardized Uptake Value Ratio (SUVR)0.9051 SUVRStandard Deviation 0.046
Comparison: Linear Regression of DRS Scores and Whole Brain GE180 SUVR in Control Subjectsp-value: 0.76Regression, Linear
Comparison: Linear Regression of MoCA Scores and Whole Brain GE180 SUVR in Control Subjectsp-value: 0.49Regression, Linear
Comparison: Linear Regression of DRS Scores and Whole Brain GE180 SUVR in MCI Subjectsp-value: 0.93Regression, Linear
Comparison: Linear Regression of MoCA Scores and Whole Brain GE180 SUVR in MCI Subjectsp-value: 0.54Regression, Linear
Comparison: Linear Regression of DRS Scores and Whole Brain GE180 SUVR in AD Subjectsp-value: 0.77Regression, Linear
Comparison: Linear Regression of MoCA Scores and Whole Brain GE180 SUVR in AD Subjectsp-value: 0.61Regression, Linear
Comparison: Linear Regression of DRS Scores and Whole Brain GE180 SUVR in PD Subjectsp-value: 0.11Regression, Linear
Comparison: Linear Regression of MoCA Scores and Whole Brain GE180 SUVR in PD Subjectsp-value: 0.84Regression, Linear

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026